PRMR 2025-2026 Recommendations Spreadsheet

Please see attached. 

Please see attached comments in support of the Low Density Lipoprotein Cholesterol (LDL-C) Monitoring and Management

MUC ID

MUC2025-034

See PACH's comment letter attached.

Please see the attached letter for our comments on the PRMR Committee Recommendation for the LDL-C Monitoring and Management (MUC2025-034) measure.

Please see attached comments. 

Please see attached comments from the National Lipid Association. 

Patients for Patient Safety US (PFPS US) submits this comment in support of MUC2025-042 (Rate of Timely Follow-up on Abnormal Screening Mammograms for Breast Cancer Detection) and urges CMS to include it in the Proposed Rule for FY2027 to solicit further comment.  Though it did not reach the consensus threshhold vote in the Partnership for Quality Measurement Committee review process, the majority of Committee members supported it.  PFPS US therefore believes this eCQM deserves further consideration.  Currently the MIPS program does not have any related measures that examine timely follow-up for abnormal breast screening mammograms. This measure fills an important gap, given the potential to significantly reduce harm and death. Breast cancer is the second most common cause of cancer deaths among women in the United States. In 2025, around 42,170 women will die from breast cancer, and an estimated 316,950 new cases of invasive breast cancer will be diagnosed.  Breast cancer survival is dependent upon cancer stage at diagnosis. Approximately 99% of women diagnosed with early-stage breast cancer live for 5 years or more. However, survival is only about 32% for those diagnosed at the most advanced stage.  

Patients for Patient Safety US (PFPS US) urges CMS to include MUC2025-043 (Rate of Timely Follow-up on Positive Stool-based Tests for Colorectal Cancer Detection) in its Proposed Rule for FY 2027.  While this eCQM measure failed to reach the consensus threshold in the Partnership for Quality Measure review committee vote, the majority of members voted in favor.  Given the potential of the measure to significantly reduce death and harm, PFPS US believes it deserves consideration and expanded opportunity for public comment in the Proposed Rule. Colorectal cancer is the second leading cause of cancer mortality in the United States for men and women combined.  In 2025, around 107,320 patients will be diagnosed with colorectal cancer and 53,010 are expected to die from it. Early detection and removal of colorectal polyps and early-stage cancers prevents disease progression and improves the odds of survival. Currently there are no related measures that examine timely follow-up for positive stool-based colorectal screening tests; therefore, this measure fills an important gap.  It also furthers CMS's eCQM strategy, which PFPS US strongly supports.

Patients for Patient Safety US (PFPS US) supports this modernized VTE measure, thinks it belongs in the HAC reduction program, thinks it will reduce preventable harm or death if implemented, and thanks CMS for including it in this year's MUC list. As a digital measure leveraging EHR data, this outcome measure adds no additional time burden and would serve as a complement to PSI-12 which relies on claims data limited to Medicare fee-for-service patients and diagnosis codes. We believe that implementing this measure will incentivize hospitals to take steps to use well-established, evidence-based strategies to reduce incidence of VTEs and improve patient outcomes. We note that it has been submitted for endorsement, one of the reasons cited for the Hospital Committee's failure to recomend it.  We urge CMS to resubmit it as expeditiously after endorsement as feasible. CMS cites that during 2019, 2021, and 2022, patients in the United States experienced 51,586 perioperative VTEs. There is clearly room for improvement by incentivizing more hospitals to follow evidence-based best practices.